Schizophrenia | Outpatient | Neurocrine | NBI-1117568-SCZ3032

schizophrenia

Nov 13

About the Study

This is a phase 3 open-label study evaluating the long-term safety and tolerability of the drug NBI-1117568 in the treatment of adults with schizophrenia.

This study is sponsored by Neurocrine Biosciences, Inc.

Eligibility

You may be eligible to participate in this study if you:

are between the ages of 18–65 years old
meet DSM-5 criteria for schizophrenia
are currently NOT experiencing an acute exacerbation or relapse of psychotic symptoms
have had a positive response to at least one antipsychotic treatment (excluding Clozapine) as confirmed by medical records

If you are interested in participating in this clinical trial, please call our friendly staff at 801-871-5516 today. You can also fill out the contact form below.

schizophrenia

Jamie Robison

Schizophrenia | Outpatient | Neurocrine | NBI-1117568-SCZ3032

About the Study

Eligibility

Clinical trials advance medicine for the benefit of communities everywhere.
Inner Space Research provides patients access to emerging therapies and generates the rigorous data regulatory agencies need to evaluate their safety and efficacy.

Inner Space Research LLC

Schizophrenia | Outpatient | Neurocrine | NBI-1117568-SCZ3032

About the Study

Eligibility

Clinical trials advance medicine for the benefit of communities everywhere.Inner Space Research provides patients access to emerging therapies and generates the rigorous data regulatory agencies need to evaluate their safety and efficacy.

Inner Space Research LLC

Clinical trials advance medicine for the benefit of communities everywhere.
Inner Space Research provides patients access to emerging therapies and generates the rigorous data regulatory agencies need to evaluate their safety and efficacy.